AvailableEXPANDED_ACCESS

(Bispecific) Antibodies in Cancer Patients

This study is exploring new treatments for people with advanced cancer when other standard treatments have been tried or aren't suitable. The treatment involves a type of medicine called 'bispecific antibodies.' These are specially designed treatments which act like a bridge, helping your own immune system find and attack cancer cells. The doctors running this study are trying to offer a new potential treatment route for patients who have very few other options left. All the treatments used in this study are developed by the lead researcher, Professor Helmut Salih. This is an important step in finding new ways to fight cancer, especially for those with complex or aggressive forms of the disease. It's about personalising care when standard approaches are no longer enough.

At a glance

Status

Available

Sponsor

University Hospital Tuebingen

Cancer

What is this study about?

This study is looking at a new type of treatment for advanced cancer using what are called 'bispecific antibodies.' You can think of antibodies as tiny scouts in your immune system that are designed to recognise and fight off harmful invaders like viruses or bacteria. Bispecific antibodies are extra special because they have two arms: one arm is designed to stick to your cancer cells, and the other arm is designed to grab onto your own immune cells. By bringing these two together, the aim is to help your immune system recognise and destroy the cancer more effectively.

This is for people with serious cancers, both those affecting solid organs (like lung or breast cancer) and those affecting blood (like leukaemia or lymphoma), where current standard treatments are no longer working or aren't available. The main goal is to offer a new treatment option when other choices are limited.

The treatments used in this study have been developed and made by the lead researcher, Professor Helmut Salih. This means the study is focused on exploring these new, specially created treatments to see if they can help patients fight their cancer when other options have been exhausted.

Key takeaways

This study uses new immune treatments for advanced cancer.
It's for people whose standard treatments are no longer working.
The new treatments are called 'bispecific antibodies'.
They aim to help your immune system fight the cancer.
The treatments are developed by the lead researcher.
You can withdraw from the study at any time.

Who may be eligible?

To be considered for this study, you must have a confirmed diagnosis of advanced cancer, where standard treatments are no longer an option. It's important that you are generally well enough to take part and your doctors believe you have a life expectancy of more than three months. You also need to be able to understand what the study involves and agree to participate by signing a consent form.

There are also some reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, you won't be able to take part. Also, if you've recently had other treatments that have caused serious side effects, or if you're taking part in another clinical study that might interfere with this one, you might not be eligible. The medical team will check all these details carefully to make sure the study is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do I have a serious, advanced cancer diagnosis?
Have I tried standard cancer treatments, and are there no other standard options left for me?
Do I feel well enough most of the time to take part in medical appointments?
Am I able to understand and sign a consent form?
Am I pregnant or breastfeeding? (If yes, you likely can't join)
Have I recently had severe side effects from past cancer treatment?

Answer every question to see your result.

What does participation involve?

The information provided doesn't detail the full schedule, but typically, taking part in a study like this would involve regular visits to the hospital or clinic. These visits are important for the medical team to monitor your health, check how you're responding to the treatment, and manage any side effects. You would receive the bispecific antibody treatment as prescribed by the study doctors. You might need blood tests, scans, or other examinations at various points. The total duration of your participation would depend on how you respond to the treatment and the study's design. Throughout your involvement, you would be expected to follow specific instructions and attend all scheduled appointments.

Potential risks and benefits

While there's no guarantee, a potential benefit of joining this study is getting access to a new, experimental cancer treatment when standard options have run out. This treatment might help slow down your cancer or improve your quality of life. However, like all new medicines, these bispecific antibodies could have side effects, some of which might be serious. The medical team will monitor you closely for any issues. It's important to remember that you can decide to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

University Hospital Tuebingen
Verified postcode
Tübingen, Germany· Available

Common questions

What is an 'advanced malignant disease'?

This means your cancer has spread or grown significantly and is considered serious, often when standard treatments are no longer effective.

What are 'bispecific antibodies'?

These are special medicines that help your body's immune system target and fight cancer cells more effectively. They act like a bridge between your immune cells and cancer cells.

Why are standard treatments not an option for this study?

This study is designed for people who have exhausted standard treatments, meaning those options haven't worked for them or aren't suitable for their specific type of cancer at this stage.

Will I get this treatment if I join the study?

If you meet all the requirements and are accepted into the study, you would receive the bispecific antibody treatment being investigated.

Is this a German study?

The ethics for patient treatment in this study follow German law, and the treatments are developed by a German professor, suggesting the research originates there, although the study could potentially recruit internationally.

How to find out more

Helmut R. Salih, Prof.

helmut.salih@med.uni-tuebingen.de +497071/2983275 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.